Moreover, targeted studies focused on elucidating the specific roles of key molecular targets, such as Beclin1, mTOR, and Smad2/3, may reveal promising avenues for the development of novel therapeutic strategies to combat ALI in septic patients. This evidence concerns the gene BECN1 and acute respiratory distress syndrome.